Revenues grew 30.9% YoY to Rs 1575 crore , primarily led by strong performance in CDMO business followed by API business
EBITDA Margins witnessed a minimal decline of ~19 bps to 28.5%, mainly due to higher raw material expenses. EBITDA increased 30% YoY to Rs 449 Crore
PAT increased 15.6 % YoY to Rs 233 Crore, declined 7.1% QoQ
CDMO business reported a strong growth of 24.8 % QoQ at Rs720 crores, supported by accelerated demand from new and existing clients
FDF revenues declined by 70% to 149 cr, mainly dragged by lower ARV business. Key factors impacting were lower volumes and lower pricing
Generic API’s saw a 29% growth YoY driven by unprecedented growth in Other API which increased 93.5% YoY to Rs 224 Crores , further supported by sustained ARVs rebound of 21% YoY to Rs408 Crore
Laurus Bio reported a soft quarter, pegged 3.8 % percent at Rs27 crore
Laurus numbers were in line with our estimates on the revenue front as well as on profitability front. CDMO business continued to deliver stellar numbers, but formulations witnessed significant dent due to poor ARV offtake. The management expects recovery from next quarter onwards on the back of two big launches in Europe. Oncology API revenues suffered this quarter due to less offtake of a key product, expected to show growth in H2FY23. We remain positive on the company’s growth story especially in the CDMO space.
ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Centre, H. T. Parekh Marg, Churchgate, Mumbai - 400020, India, Tel No : 022 - 2288 2460, 022 - 2288 2470.I-Sec is a SEBI registered with SEBI as a Research Analyst vide registration no. INH000000990.. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The information mentioned herein above is only for consumption by the client and such material should not be redistributed.
The information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities Limited. The contents of this mail are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. While due care has been taken in preparing this mail, I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any inaccurate, delayed or incomplete information nor for any actions taken in reliance thereon. This mail is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject I-Sec and affiliates to any registration or licensing requirement within such jurisdiction